Anti-Alzheimer's disease

Folic acid
Catalog No: CFN98552

Folic acid supplementation improves arterial endothelial function in adults with relative hyperhomocystinemia, with potentially beneficial effects on the atherosclerotic process. Both local perfusion of 5-MTHF and supplementation with folic acid increase vasodilatation in ageing individuals through NO-dependent mechanisms. The combined use of enalapril and Folic acid significantly reduced the risk of first stroke, folic acid deficiency and homocysteine impaired DNA repair in hippocampal neurons and sensitized them to amyloid toxicity.

Medioresinol
Catalog No: CFN98641

Medioresinol possesses antioxidative, a lesishmanicidal activity and cardiovascular disease risk reduction, it has antiamyloidogenic activity via reduction in the amount of β-secretase, it is a potentially valuable antiamyloidogenic agent for the prevention and treatment of Alzheimer disease. (+)-Medioresinol has anti-bacterial, antifungal and anti-biofilm activities.

Talatisamine
Catalog No: CFN98580

Talatisamine is a newly identified K+ channel blocker with hypotensive and antiarrhythmic activities. Talatisamine (120 μM) and TEA (5mM) inhibits the enhanced I(K) caused by Aβ40 oligomers, attenuates cytotoxicity of Aβ oligomers by restoring cell viability and suppressing K(+) loss related apoptotic response.

Tabersonine
Catalog No: CFN98678

Tabersonine is a precursor for vincristine used in cancer chemotherapy, the biocompatibility and small size essential for permeating the blood-brain barrier make it a potential therapeutic drug candidate for treating AD.

Vasicine
Catalog No: CFN97052

Vasicine, a potential natural cholinesterase inhibitor, has been in development for treatment of Alzheimer's disease. Vasicine can regulate the inflammatory reaction, have great potentials to develop safe medications for respiratory and reproductive medicine.Vasicine is also oxytocic and abortifacient agents.